Although molecular targeted therapies, such as targeting human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR-2), and Claudin18.2, have achieved treatment improvement in recent years, not all patients’ tumor cells have specific targets (7). Here, ERBB2 is linked to neoplasm.